23:01 , Apr 19, 2019 |  BC Extra  |  Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

In a busy week for Boston-area biotechs, at least two companies debuted -- microbiome-mimicking small molecule company Kintai and pain play Nocion -- while a third, Arrakis, raised a $75 million series B round. Kintai...
21:28 , Apr 18, 2019 |  BC Extra  |  Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

Arrakis raised $75 million in a series B round led by venBio and Nextech Invest. Also participating were new investors Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and Alexandria Venture...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
23:41 , Feb 7, 2019 |  BC Innovations  |  Finance

Pharma ventures earlier

Facing the squeeze from inside and out, at least three corporate venture arms are revamping operations to increase their foothold in earlier and riskier investment opportunities. From one side, the move reflects the growing reliance...
11:33 , Nov 13, 2018 |  BioCentury  |  Finance

Playing in RNA

M Ventures, the strategic venture arm of Merck KGaA (Xetra:MRK), is adding another RNA company to its portfolio by leading a $30 million series A round for Ribometrix Inc. Fellow new investors Amgen Ventures, Pappas...
21:45 , Oct 12, 2018 |  BioCentury  |  Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series...
00:52 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

RNA party

A study in Cell has uncovered a brain regulatory network involving a circular RNA, a long non-coding RNA and two microRNAs, and could provide some much needed insights in a field where finding links to...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
00:06 , Jun 28, 2018 |  BC Extra  |  Company News

Management tracks: Arrakis, Astellas

Arrakis Therapeutics Inc. (Waltham, Mass.) founder and CSO Russ Petter is transitioning to Jennifer Petter. The news was announced in a blog post by Chairman and CEO Michael Gilman. "The support for this transition at...